RANEXA 500 MG

Pays: Israël

Langue: anglais

Source: Ministry of Health

Ingrédients actifs:

RANOLAZINE 500 MG

Disponible depuis:

NEOPHARM LTD

Code ATC:

C01EB18

forme pharmaceutique:

TABLETS EXTENDED RELEASE

Mode d'administration:

PER OS

Fabriqué par:

CV THERAPEUTICS INC, USA

Groupe thérapeutique:

RANOLAZINE

indications thérapeutiques:

Ranexa is indicated for the treatment of chronic angina. Ranexa is also indicated as add-on therapy for the symptomati treatment of patients with chronic angina who are inadequately controlled or intolerant to other first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).Ranexa may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers.

Date de l'autorisation:

2010-10-01